Key result
Current use of non-cardiovascular hERG channel blockers was associated with an increased risk of sudden cardiac death, especially for drugs with high hERG-channel-inhibiting capacity.
Why the study?
Does the use of non-cardiovascular hERG channel blockers increase the risk of sudden cardiac death in the general population?
Population
1,424 cases of sudden cardiac death and 14,443 matched controls from the Integrated Primary Care Information…
Comparison
Current use of non-cardiovascular hERG channel… vs Matched controls and users of drugs with low…
Design
Case-control
Authors
Loading...
May warrant caution with high-potency non-cardiovascular hERG blockers; leaves open causality pending prospective studies.
Case-Control (n=15,867)
Does the use of non-cardiovascular hERG channel blockers increase the risk of sudden cardiac death in the general population?
Non-cardiovascular drugs that strongly inhibit hERG potassium channels are associated with an increased risk of sudden cardiac death in the general population.
Noord et al. (2010) conducted a case-control in Sudden cardiac death (n=15,867). Non-cardiovascular hERG channel blockers vs. Matched controls was evaluated on Sudden cardiac death. Current use of non-cardiovascular hERG channel blockers was associated with an increased risk of sudden cardiac death, especially for drugs with high hERG-channel-inhibiting capacity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: